Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden

Haemophilia

Volumn 10, Issue 5, 2004, Pages 515-526

  Steen Carlsson, Katarina ^a,f   Hojgard S ^a,f   Lindgren, A ^b   Lethagen, S ^a,f   Schulman, S ^c   Glomstein, A ^d   Tengborn, L ^e   Berntorp, E ^a,f   Lindgren, B ^a,f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND INSTITUTE OF TECHNOLOGY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Rikshospitalet   (Norway)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Cost; Longitudinal data analysis; On demand; Prophylaxis; Sensitivity analysis

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DEATH; DISEASE SEVERITY; FACTORIAL ANALYSIS; HEALTH CARE COST; HEMOPHILIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NORWAY; PRESCRIPTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SWEDEN;

ADULT; AGED; HEALTH CARE COSTS; HEMOPHILIA A; HEMORRHAGE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NORWAY; REGRESSION ANALYSIS; SWEDEN;

EID: 4844222412     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00952.x     Document Type: Article

References (32)

1. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
2. Aledort L, Hashmeyer R, Pettersson H, Group at OOS. A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
3. Nilsson I-M. Hemophilia. Stockholm, Sweden: Pharmacia Plasma Products, 1994.
4. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
5. Steen Carlsson K, Höjgåd S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
6. Berntorp E. Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment. Haemophilia 1995; 1(Suppl. 1): 3-7.
7. Carlsson M. Pharmacokinetic Dosing of Factor VIII and Factor IX in Prophylactic Treatment of Haemophilia, in Department for Coagulation Disorders (Department of Medicine). Malmö, Sweden: Lund University, 1997.
8. Kasper C, Dietrich S, Rapaport S. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125: 1004-9.
9. Petrini P, Lindwall N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13: 280-7.
10. Nilsson I, Berntorp E, Ljung R, Löfqvist T, Pettersson H. Prophylactic treatment of severe hemophilia A and B can prevent joint disability. Semin Hematol 1994; 31(Suppl. 2): 5-9.
11. Ross-Degnan D, Soumerai S, Avorn J, Bohn R, Bright R, Aledort L. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995; 11: 327-44.
12. Miners A, Sabin C, Tolley K, Lee C. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med 2000; 247: 493-9.
13. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
14. Miners A, Sabin CA, Tolley K, Lee C. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002; 20: 759-74.
15. Steen Carlsson K, Höjgård S, Lethagen S, Berntorp E, Lindgren B. Economic evaluation: What are we looking for and how do we get there? Haemophilia 2004; 10(Suppl. 1): 44-9.
16. Steen Carlsson K, Höjgård S, Lethagen S, Lindgren A, Berntorp E, Lindgren B. Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden. Haemophilia 2004; 10: 527-41.
17. Goudemand J. Treatment of patient with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
18. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications, Oxford, UK: Oxford University Press, 1997.
19. Becker G. Human Capital. A Theoretical and Empirical Analysis, with Special Reference to Education, 2nd edn. New York, NY: National Bureau of Economic Research, 1975.
20. Baltagi B. Econometric Analysis of Panel Data. New York, NY: Wiley and Sons, 1995.
21. Zerbe R, Dively D. Benefit-Cost Analysis in Theory and Practice. New York: Harper Collins, 1994.
22. Viscusi K. Fatal Tradeoffs. Public and Private Responsibilities for Risk. Oxford, UK: Oxford University Press, 1992.
23. Persson U, Norinder A, Hjalte K, Gralén K. The value of a statistical life in transport: findings from a new contingent valuation study in Sweden. J Risk Uncertainty 2001; 23: 121-34.
24. Fischer K, van der Bom J, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
25. Walker I, Julian J. Causes of death in Canadians with haemophilia 1980-1995. Haemophilia 1998; 4: 714-20.
26. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in hemophiliacs treated with low-purity factor VIII. Lancet 1993; 343: 462-4.
27. Bray G, Gomperts E, Courter S, Gruppo R, Gordon E, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
28. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, The Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453-9.
29. Nilsson I, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Inter Med 1992; 232: 25-32.
30. Berntorp E, Hansson B, Böttiger B et al. HIV seroconversion in Swedish haemophiliacs: relation to type and dosage of factor concentrate. Eur J Haematol 1987; 38: 256-60.
31. Fischer K, Astermark J, Van Der Bom JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60.
32. Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: background, rationale and design. Haemophilia 2003; 9(Suppl. 1): 44-9.